VERV Valuation
Verve Therapeutics Inc
$
11.200
- Overview
- Forecast
- Valuation
- Earnings
VERV Relative Valuation
VERV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VERV is overvalued; if below, it's undervalued.
Historical Valuation
Verve Therapeutics Inc (VERV) is now in the Undervalued zone, suggesting that its current forward PS ratio of 46.82 is considered Undervalued compared with the five-year average of -7.30. The fair price of Verve Therapeutics Inc (VERV) is between 49.65 to 53.05 according to relative valuation methord. Compared to the current price of 11.20 USD , Verve Therapeutics Inc is Undervalued By 77.44%.
Relative Value
Fair Zone
49.65-53.05
Current Price：11.20
77.44%
Undervalued
-3.98
PE
1Y
3Y
5Y
Trailing
Forward
-1.98
EV/EBITDA
Verve Therapeutics Inc. (VERV) has a current EV/EBITDA of -1.98. The 5-year average EV/EBITDA is -5.03. The thresholds are as follows: Strongly Undervalued below -18.73, Undervalued between -18.73 and -11.88, Fairly Valued between 1.82 and -11.88, Overvalued between 1.82 and 8.66, and Strongly Overvalued above 8.66. The current Forward EV/EBITDA of -1.98 falls within the Historic Trend Line -Fairly Valued range.
-2.03
EV/EBIT
Verve Therapeutics Inc. (VERV) has a current EV/EBIT of -2.03. The 5-year average EV/EBIT is -5.16. The thresholds are as follows: Strongly Undervalued below -19.95, Undervalued between -19.95 and -12.56, Fairly Valued between 2.23 and -12.56, Overvalued between 2.23 and 9.63, and Strongly Overvalued above 9.63. The current Forward EV/EBIT of -2.03 falls within the Historic Trend Line -Fairly Valued range.
46.82
PS
Verve Therapeutics Inc. (VERV) has a current PS of 46.82. The 5-year average PS is 308.28. The thresholds are as follows: Strongly Undervalued below -572.65, Undervalued between -572.65 and -132.19, Fairly Valued between 748.75 and -132.19, Overvalued between 748.75 and 1189.22, and Strongly Overvalued above 1189.22. The current Forward PS of 46.82 falls within the Historic Trend Line -Fairly Valued range.
-5.08
P/OCF
Verve Therapeutics Inc. (VERV) has a current P/OCF of -5.08. The 5-year average P/OCF is -8.60. The thresholds are as follows: Strongly Undervalued below -25.96, Undervalued between -25.96 and -17.28, Fairly Valued between 0.08 and -17.28, Overvalued between 0.08 and 8.75, and Strongly Overvalued above 8.75. The current Forward P/OCF of -5.08 falls within the Historic Trend Line -Fairly Valued range.
-4.30
P/FCF
Verve Therapeutics Inc. (VERV) has a current P/FCF of -4.30. The 5-year average P/FCF is -7.32. The thresholds are as follows: Strongly Undervalued below -19.84, Undervalued between -19.84 and -13.58, Fairly Valued between -1.06 and -13.58, Overvalued between -1.06 and 5.20, and Strongly Overvalued above 5.20. The current Forward P/FCF of -4.30 falls within the Historic Trend Line -Fairly Valued range.
Verve Therapeutics Inc (VERV) has a current Price-to-Book (P/B) ratio of 2.08. Compared to its 3-year average P/B ratio of 1.83 , the current P/B ratio is approximately 13.75% higher. Relative to its 5-year average P/B ratio of 2.57, the current P/B ratio is about -18.95% higher. Verve Therapeutics Inc (VERV) has a Forward Free Cash Flow (FCF) yield of approximately -14.85%. Compared to its 3-year average FCF yield of -20.73%, the current FCF yield is approximately -28.35% lower. Relative to its 5-year average FCF yield of -16.65% , the current FCF yield is about -10.78% lower.
2.08
P/B
Median3y
1.83
Median5y
2.57
-14.85
FCF Yield
Median3y
-20.73
Median5y
-16.65
Competitors Valuation Multiple
The average P/S ratio for VERV's competitors is 816.13, providing a benchmark for relative valuation. Verve Therapeutics Inc Corp (VERV) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 479.03%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of VERV increased by 66.12% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 5.70M to 32.98M.
The secondary factor is the Margin Expansion, contributed -89.00%to the performance.
Overall, the performance of VERV in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
MATV
Mativ Holdings Inc
10.410
USD
+10.63%
NNDM
Nano Dimension Ltd
1.380
USD
+3.76%
FFWM
First Foundation Inc
5.230
USD
+6.30%
UHT
Universal Health Realty Income Trust
39.650
USD
+2.91%
SHBI
Shore Bancshares Inc
15.880
USD
+3.99%
FLWS
1-800-Flowers.Com Inc
5.530
USD
+1.65%
DDI
DoubleDown Interactive Co Ltd
9.520
USD
+0.21%
RSVR
Reservoir Media Inc
7.730
USD
+0.39%
SBC
SBC Medical Group Holdings Inc
4.540
USD
+2.25%
PSBD
Palmer Square Capital BDC Inc
14.050
USD
+1.15%
FAQ
Is Verve Therapeutics Inc (VERV) currently overvalued or undervalued?
Verve Therapeutics Inc (VERV) is now in the Undervalued zone, suggesting that its current forward PS ratio of 46.82 is considered Undervalued compared with the five-year average of -7.30. The fair price of Verve Therapeutics Inc (VERV) is between 49.65 to 53.05 according to relative valuation methord. Compared to the current price of 11.20 USD , Verve Therapeutics Inc is Undervalued By 77.44% .
What is Verve Therapeutics Inc (VERV) fair value?
How does VERV's valuation metrics compare to the industry average?
What is the current P/B ratio for Verve Therapeutics Inc (VERV) as of Aug 13 2025?
What is the current FCF Yield for Verve Therapeutics Inc (VERV) as of Aug 13 2025?
What is the current Forward P/E ratio for Verve Therapeutics Inc (VERV) as of Aug 13 2025?